Market Overview

Kite Pharma Spiking After Release Of Positive Clinical Data

Kite Pharma Spiking After Release Of Positive Clinical Data
Related KITE
Gilead Looking To Buy Incyte? It Makes Sense
RBC Hints At Potential M&A For Kite Pharma
The Vetr community has downgraded $KITE to 3-Stars (Vetr)

Kite Pharma Inc (NASDAQ: KITE) announced positive topline data from the PII ZUMA-1 study in NHL.

“We view the 3-month CR rate across the entire ZUMA-1 cohort as favorable and suggestive of a durable response,” Jefferies’ Biren Amin said in a report. He maintained a Buy rating on the company, with a price target of $72.

“The ZUMA-1 study pre-defines duration of response as inclusive of all three pt cohorts, and therefore we think the trial should observe a >6 months duration of response which view as a key marker for regulatory approval,” Amin wrote.

Related Link: Juno Therapeutics Viewed As A Sympathy Play On Kite Pharma's KTE-C19

More Information Awaited

The results support the approvability of KTE-C19 and Kite Pharma is likely to offer more details around its commercial aspects during the investor day on October 18. The company would also likely provide a breakdown of the Phase II data by patient subgroup/characteristics during ASH in December.

Durability Of KTE-C19 In NHL

Amin believes that the FDA would be most interested in the durability of response when evaluating the efficacy of KTE-C19 and that Kite Pharma has set a bar of 6.6 months for mOS based on the Scholar 1 study in a similar patient population.

“Although the PII durability data is immature, we view the CR rate at 3 months follow up to be a reasonable proxy for durability at this juncture and believe that most of the CR responses ongoing at 3-months should remain durable,” the analyst wrote.

Shares of Kite Pharma surged more than 8 percent by 10:55 a.m. ET.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for KITE

Mar 2017Standpoint ResearchDowngradesBuyHold
Mar 2017Stifel NicolausDowngradesBuyHold
Mar 2017CitigroupDowngradesBuyNeutral

View More Analyst Ratings for KITE
View the Latest Analyst Ratings

Posted-In: Biren AminAnalyst Color Long Ideas Health Care Reiteration Analyst Ratings Trading Ideas General Best of Benzinga


Related Articles (KITE)

View Comments and Join the Discussion!